ArticleNeuro-oncology advances

Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.

Hajime Yonezawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.